CHS-1420

BIOLOGICAL2 trials

Sponsors

Coherus Oncology, Inc., Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.

Conditions

Healthy ParticipantsPlaque Psoriasis

Phase 1

A Trial to Assess the Pharmacokinetic Similarity Between CHS-1420 40 mg/0.4 mL and HUMIRA® (Adalimumab) 40 mg/0.4 mL in Healthy Chinese Adult Participants Under Fasting Conditions

CompletedNCT07147257

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.Healthy Participants

Start: 2025-02-12End: 2025-05-29Updated: 2026-01-28

Phase 3

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

CompletedNCT02489227

Coherus Oncology, Inc.Plaque Psoriasis

Start: 2015-08-31End: 2017-03-31Updated: 2020-04-08

Related Papers

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Annals of the Rheumatic Diseases2018-03-07112 citations